David Ku, M.D.

David Ku joined Jasper Therapeutics in 2020 and has led business development and finance, including leading Jasper’s partnerships with the NHLBI, NIAID and NCI institutes of the NIH as well as gene therapy partners at Graphite Bio and AVROBIO. He has supported the company’s financing, raising over $100M in new capital from taking Jasper public in 2021. In addition to corporate development, he now leads Jasper’s program team for briquilimab (JSP191) in chronic diseases and stem cell transplant for rare diseases.

Prior to Jasper, he worked at Gilead in strategic planning and at McKinsey as a consultant in the Life Sciences Practice. While at McKinsey, he served biotech and pharma clients on R&D strategy, portfolio management and asset evaluation. Dr. Ku received his M.D. with distinction from the Mount Sinai School of Medicine and S.B. in Computer Science from MIT.